Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection â a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities. Source
No articles found.
NuvectraÂŽ is a neurostimulation company committed to helping physicians improve t...
NuvectraÂŽ is a neurostimulation company commit...
CHF Solutions is focused on improving the quality of life for patients suffering f...
CHF Solutions is focused on improving the quali...
With operations in South San Francisco, CA and Research Triangle Park, NC, Satsuma...
With operations in South San Francisco, CA and ...
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company foc...
Founded in November 2012, ObsEva is a clinical-...
Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...
Alnylam is leading the translation of RNA inter...
ARCA was founded on the belief that a precision medicine approach to drug developm...
ARCA was founded on the belief that a precision...
Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transfo...
Jounce Therapeutics is a clinical stage immunot...
Join the National Investor Network and get the latest information with your interests in mind.